UsAgainstAlzheimer’s Proposes Key Measures to Advance Treatment Development
As the disappointment over the failure of solanezumab begins to wane, George Vradenburg, co-founder and chairman of UsAgainstAlzheimer’s, seeks to address the efforts needed to continue research and clinical development for Alzheimer’s disease. Despite the inability of Eli Lilly to bring the goods to the table, Vradenburg applauded Lilly’s…